ArticleHealth science reports2026
CRISPR-Cas9 in Cancer Therapy: Overcoming Delivery Barriers and Off-Target Effects for Clinical Translation.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: CRISPR-Cas9 gene editing has transformed molecular biology and has great potential as a therapeutic tool for cancer and many other human diseases. This perspective review elaborates on the recent advances in CRISPR-Cas9 technology and its application as an innovative cancer treatment. Additionally, this perspective outlines the current barriers to clinical translation, including Discussion: CRISPR-Cas9 has enabled the development of innovative methods to enhance immunotherapy, overcome drug resistance, and identify new therapeutic targets. Importantly, CRISPR-Cas9-induced DNA double-strand breaks can activate p53-mediated selection and cause unintended on-target genomic alterations, including large deletions, chromosomal rearrangements, and chromosome loss. While progress has been made toward addressing these significant obstacles, optimizing delivery systems, minimizing off-target effects, and addressing immunogenicity are critical for the successful clinical application of CRISPR-Cas9. Emerging strategies, including high-fidelity Cas9 variants, optimized guide RNAs, and advanced non-viral delivery systems such as lipid nanoparticles (LNPs) and exosomes, may improve the precision, safety, and delivery of CRISPR-Cas9-based therapies. Continued innovation in base editing and prime editing may enable the development of more refined approaches for precise genome modification. Conclusion: From a translational perspective, we argue that improvements in editing efficiency alone will be insufficient; clinical success will require the simultaneous achievement of tumor-selective delivery, genomic integrity, and acceptable long-term safety. Therefore, the continued development of novel approaches should be promoted to realize the full potential of CRISPR-Cas9 technology in oncology and other therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.